Stryker Corporation vs ProShares Ultra Gold ETF — how do they compare? Stryker Corporation trades at $277.34 (market cap $106.24B), while ProShares Ultra Gold ETF trades at $46.47 (market cap $716.59M). The key difference: Stryker Corporation is far larger — about 148.3× ProShares Ultra Gold ETF's market cap, and Stryker Corporation pays a 1.27% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and ProShares Ultra Gold ETF for 23 Days on average.
| SYK | UGL | |
|---|---|---|
Market Cap | $106.24B | $716.59M |
Volume | 2,982,001 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.35 | $85.62 |
52-Week Low | $269.75 | $42.79 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $117.70B | — |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
UGL trades at $46.47, up 4.59% in the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing to selling pressure. Key support lies at $44, while resistance is near $46. The stock lacks disclosed financial ratios, limiting fundamental visibility. Recent news highlights gold price volatility driven by Treasury yields and Federal Reserve policy expectations, influencing sentiment around gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds from rising rates. Investment opportunity hinges on gold price stabilization, but risks include persistent bearish indicators and sensitivity to interest rate changes. Investors should await clearer fundamental data and technical confirmation of a trend reversal before considering entry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →